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Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, 
partly depending on demographics and biomarker status. The aim of the present study was to survey 
the clinical practices of physicians in terms of biomarker counselling, management, and follow-up 
in European expert centers diagnosing patients with MCI. 
 
Methods 
An online email survey was distributed to physicians ffiliated with European Alzheimer’s Disease 
Consortium centers (Northern Europe: 10 centers; Eatern and Central Europe: 9 centers; Southern 
Europe: 15 centers) with questions on attitudes towards biomarkers and biomarker counselling in 
MCI and dementia. This included post-biomarker counselling and the process of diagnostic 
disclosure of MCI, as well as treatment and follow-up in MCI. 
 
Results 
The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority 
of physicians had access to biomarkers and found them useful. Pre- and post-biomarker counselling 
varied across centers, as did practices for referral to support groups and advice on preventive 




















The variability in clinical practices across centers calls for better biomarker counselling and better 
training to improve communication skills. Future initiatives should address the importance of 
communicating preventive strategies and advance planning. 
 
Keywords: mild cognitive impairment, dementia, diagnostic disclo ure, biomarker counselling, 
biomarkers, Alzheimer’s disease, survey, diagnosis 
Key points 
• Physicians’ practice regarding biomarker counselling, disclosure of diagnosis and follow-up 
in patients with mild cognitive impairment is not known; 
• Practices varied across European centers with regards to a number of issues including 
biomarker counselling and preventive strategies 
• Communications training and development of guidelines on these issues may help to 
improve practices and realize less variability 
 
 































A growing number of patients are referred for diagnostic evaluation of possible cognitive 
impairment. This is presumably due to, in part, an increasing prevalence of dementia worldwide 1,2 
but may also be driven by an increased awareness of dementia in the population at large and among 
physicians 3. Stakeholders also highlight the need for early diagnosis prior to the stage of dementia 
to enable adequate support and possibly, in the future, he ability to offer early disease-modifying 
therapy 4. This is likely to increase the number of patients diagnosed with more subtle cognitive 
impairment, which include patients without dementia but with an underlying neurodegenerative 
disease and other possibly non-progressive conditios. 
 
The term mild cognitive impairment (MCI) was created o capture a group of those patients with 
objectively measurable cognitive impairment not fulfilling the criteria for dementia (e.g., no 
impairment in activities of daily living) 5–7 and not necessarily related to dementia disorders. 
Although initially developed as a research tool, MCI has since been adopted into clinical practice at 
many centers. Over the years, the concept has further evolved, especially with the introduction of 
Alzheimer’s disease (AD) biomarkers and the subsequent addition of MCI due to AD and 
prodromal AD to the diagnostic criteria 8–10. Although patients with MCI have a higher risk of 
progression to dementia 11, this risk varies greatly depending on a variety factors 12. For example, in 
one study, having MCI and an abnormal biomarker of amyloid and neurodegeneration was found to 
increase the lifetime risk of a 60-year-old from 78.1% to 95.6% versus only abnormal markers of 
neurodegeneration. Moreover, the risk decreased approximately 10 percentage points for a 75 year 


















It should be kept in mind that these estimates do not convey the individual patient’s risk of 
progression but are estimates at group level. Another issue is that an age-dependent proportion of 
older people will have asymptomatic amyloidosis in the brain 14 and a relatively high incidence of 
other age-related conditions i.e. cerebrovascular disor ers which may also affect biomarkers. This is 
also reflected in the fact that ‘incidental’ amyloid sis can be found in an equivalent proportion of 
patients with dementia not usually associated with amyloid pathology 15. This highlights the 
important issue of biomarker counselling prior to and following sampling in patients with MCI and 
the ethical dilemmas inherent to early biomarker-based diagnosis 16. Other issues may make the 
term MCI difficult to administer in a clinical setting. Whereas a substantial number of patients and 
caregivers are familiar with the term dementia 3, MCI is likely to be less familiar. Moreover, 
conveying the concept of MCI, i.e., cognitive deficit but no impairment in activities of daily living, 
may be challenging.  
Studies have been conducted on the attitudes of physicians toward the concept of MCI 17, the 
perception of patients and caregivers concerning disclosure of dementia 18, the possible benefits of a 
timely diagnosis 19, and on disclosing a positive biomarker status to patients with MCI or no 
cognitive impairment 20–22. Moreover, previous surveys have examined physician pr ctices for 
diagnosing MCI, including how the diagnosis was disclo ed, the terms that were used, and follow-
u  23–25. However, little is known about how physicians who manage patients with MCI carry out 
biomarker counselling or how the results and consequences of biomarker sampling are 
communicated to patients. Additionally, there also is no clinical standard established for biomarker 
use in MCI-patients. 
 
Thus, the primary objective of the present study was to survey the clinical practices of European 

















concept of MCI and biomarker results were conveyed to patients, in addition to how the physician’s 
characteristics may influence how this is done. Finally, we assessed the guidance and management, 




2.1 Study design 
 
The present study was designed as a survey of physician  working in European Alzheimer’s 
Disease Consortium (EADC) centers. EADC is a European network of centers of excellence 
working in the field of AD and was established in 2001. The centers conduct research and carry out 
diagnosis and treatment of patients suspected of having MCI or dementia. 
 
For the present study, we developed two online questionnaires. One was sent to a coordinating 
doctor (usually a senior specialist) at participating centers and the other to individual center 
physicians regularly diagnosing and doing follow-up with patients with MCI. To identify centers 
who were interested in participating, an email was sent to the contact person at each center. Each 
center was asked to identify at least five physicians who were interested in participating.  
 
The online survey was conducted from February 1, 209 to April 31, 2019. Participants received an 
email with a link to the survey, and four rounds of reminders were sent. The questionnaire for 
coordinating physicians asked about issues on a more organizational level, while the one for 
individual physicians was divided into three sections addressing attitudes towards biomarkers and 
biomarker counselling in MCI and dementia; post-biomarker counselling and the process of 

















included sections on demographics, training, and experience. Physicians were explicitly asked to 
complete their questionnaire according to their present practice. 
 
To facilitate the statistical analysis, the survey presented answers using a five-point Likert scale of 
“Always/almost always” to “Never/almost never”; “Very well” to “Not at all”; and “To a great 
extent” to “Not at all”. Where relevant, “Don’t know” was also an option, just as space was 
available to make comments. For ease of reporting, some categories were collapsed into one. The 
data that support the findings of this study are avail ble from the corresponding author upon 
reasonable request. 
 
2.2 Statistical analysis 
 
To explore the factors associated with practice and attitudes in disclosure of diagnosis, we carried 
out statistical analyses to assess the impact of age, years of experience, whether respondents 
actively recruited patients with MCI for research, and whether respondents had received training in 
the process of disclosing a diagnosis of dementia or similar devastating conditions. This was done 
using the Mann-Whitney U test for independent samples. Where relevant, we also compared 
differences in respondent practices between patients with MCI and patients with dementia using the 
Wilcoxon signed-rank test for dependent samples. Statistical analyses were carried out using 
Intercooled Stata 9.2 for Macintosh (StataCorp LLC, College Town, Texas, USA). Level of 
significance was set at p<0.05 (two-tailed test). 
 
























All 69 EADC member centers were emailed and 42 centers agreed to participate. The response rate 
was 80.9 % (35 out of 42) for center coordinating physicians (i.e. number of questionnaires 
received from the coordinating physician on organiztional matters) and 50.6 % (110 out of 213) of 
individual physicians responded to the survey. Some coordinating physicians also completed the 
individual physician questionnaire. There was a median of three respondents per center (Range: 1–-
7). Twenty-three centers (67.7 %) were based in neurology, 7 (20.6 %) in geriatrics and 4 (11.8 %) 
in psychiatry. Centers had a median of 600 (range 200–-5000) new visits per year. Among newly 
referred patients, a median of 31.5 % (range 15–-60%) were diagnosed with MCI per month. Every 
center conducted research, and 32 conducted research th t recruited patients with MCI. Three 
European regions were represented: Northern Europe: 11 centers (Belgium 2, Denmark 1, Finland 
1, Germany 3, Ireland 1, the Netherlands 1, Sweden 1, UK 1); Eastern and Central Europe (based 
on Organisation for Economic Cooperation and Development definition) and Turkey: 9 centers 
(Czech Republic 2, Poland 1, Romania 1, Serbia 1, Slovenia 1, Switzerland 2, Turkey 1); and 
Southern Europe: 15 centers (France 5, Greece 1, Italy 3, Portugal 2, and Spain 4). All individual 
respondents reported diagnosing and following patients with MCI. The mean age of individual 
physicians was 42.1 years (standard deviation 10.1). Respondents reported having a mean of 95.6 
(range 4–160) consultations per month. Fifteen respondents (14%) reported that they were not 
involved in research, and 33 (30%) reported spending 50% or more of their time on research. Table 


















3.1 Attitudes towards biomarkers and biomarker counselli g in MCI  
Almost all respondents had access to magnetic resonance imaging (98.2%; n=108) and 
cerebrospinal fluid (CSF) sampling (91.8%; n=101), whereas fewer had access to 18F-FDG-PET 
(74.5%; n=82) and amyloid PET (50.9%; n=56). A majority reported always or usually ordering a 
magnetic resonance imaging scan (MCI: 81.8%; n=90, dementia: 76.4%; n=84), whereas less than 
half always or usually ordered cerebrospinal fluid sampling or 18F-FDG-PET (Supplementary 
Figure 1). 
 
Respondents were also asked about the value of biomarkers. Biomarkers reflecting amyloid 
pathology was found to be the most valuable to predict progression and rate of progression in MCI 
patient. Very few found that the biomarkers had no value in this respect (Figure 1, supplementary 
Figure 2).  
 
Most, but not all respondents, always or usually discussed the decision to order biomarkers with 
patients with MCI (85.7%; n=90) and dementia (81.1%; n=86). A large majority said that they 
discussed this more in-depth with patients with MCI. Individual physicians recruiting patients with 
MCI for research were more likely to do so (Table 2). Most, but not all of the respondents always or 
usually discussed the ability to diagnose the underlying etiology in patients suspected of having 
MCI (actively recruiting p=0.002) (Table 2). Fewer r spondents always or usually discussed the 
ability to predict progression (MCI: 61.0%; n=61, dementia: 68.1%; n=64) and the uncertainties of 



















3.2 Post biomarker counselling and diagnostic disclosure of MCI  
The diagnosis of dementia was found to be more meaningful to more respondents than MCI 
(p=0.0002) (Table 2). Most respondents (79.1%; n=87) never or seldom found that the diagnosis of 
MCI was unethical. For MCI disclosure guidelines, 28.3% (n=30) reported having access to 
guidelines (dementia: 46.2%; n=49).  
 
Almost all respondents disclosed the MCI diagnosis when it was suspected. Risk of progression and 
the probable underlying etiology but not the probable rate was often discussed with patients with 
MCI (Table 2). About half disclosed the risk of prog ession and underlying cause regardless of 
whether the patient asked. A substantial minority onl  did so if asked by the patient (Table 3). 
Linguistically the term reported used most often was MCI and rarely or never “a form of mild 
dementia” and “predementia stage” (Figure 2). Regarding tools used when disclosing the diagnosis 
of MCI, a little over half always or usually showed brain imaging scans, whereas about a quarter 
seldom or never showed brain imaging scans (communications training: z=.04; p=0.04) (Table 2).  
 
3.3 Management of patients with MCI 
 
Almost all respondents reported following up on MCI (95.2%; n=100) and patients with dementia 
(90.48%; n=95). Half (50.5%; n=53) reported following patients with MCI for ≥5 years and 45.3% 
(n=48) for dementia. Regarding frequency of visits, 37.7% (n=40) reported seeing patients with 
MCI twice a year, while 47.6% (n=50) did so for patien s with dementia. A total of 67.3% (n=70) 
respondents reported that local support groups wereavailable. Treatment with cholinesterase 
inhibitors in patients with MCI was offered always or usually by 23.6% (n=25) and seldom or never 

















patients started on cholinesterase inhibitors was not collected. A majority also addressed non-
pharmacological treatment (Supplementary Figure 3). 
 
A little less than half always or usually reported discussing driving when giving the MCI diagnosis, 
whereas most discussed this with patients with dementia (Table 2). A similar pattern emerged for 




Our study presents the results of a survey of 34 EADC centers of excellence working in the field of 
AD and 110 individual physicians affiliated to the c nters on various aspects of the diagnostic 
disclosure and management of MCI, including biomarker counselling. Our most important finding 
is that there is a high degree of heterogeneity across centers, particularly regarding counselling 
(e.g., pre-biomarker counselling). In addition, a relatively high number of physicians did not discuss 
preventative measures with patients or planning for the future for instance by mentioning advance 
directives.  
 
One of the arguments for early diagnosis is to offer support and possibly treatment, including the 
possibility of participating in trials with potentially disease-modifying therapy, to patients with MCI 
26. For this reason, all patients should ideally have the opportunity to participate in support groups, 
and all patients should be offered counselling on hw to mitigate the risk of progression. About 
two-thirds of respondents reported that it was possible to refer patients to local support groups. 
About three-fourths mentioned physical exercise as an intervention for MCI, and fewer than three-
fourths discussed other possible strategies to reduce the risk of progression. There was also a clear 

















diagnosed with MCI versus dementia. Although it would be logical to assume that advance 
planning is best handled at an early stage of cognitive impairment, reluctance to engage in possibly 
difficult issues may be related to the attitudes of the physician but may also be due to patient 
preference to avoid dealing with emotionally difficult issues. For many patients, the issue of 
whether the cognitive impairment may affect driving, is a sensitive one. Regardless it may be 
relevant even in patients with MCI to discuss driving, and possibly especially so in certain cognitive 
subtypes of MCI such as patients with dys-executive syndrome or prominent visuo-cognitive 
impairment. 
 
A large majority of respondents found that biomarkers were helpful in predicting progression to 
dementia in patients with MCI. Respondents saw AD biomarkers (tau and beta-amyloid) as the 
most valuable, which could indicate that MCI is often seen within a clinico-biological AD 
framework. However, CSF sampling and amyloid PET were nevertheless reported as performed in 
a minority of patients suspected of MCI in our study, which is in line with previous findings 27. This 
may be due to funding issues, reimbursement and access to PET facilities and tracers. Although 
85.1% of respondents reported always or usually discussing biomarker sampling with patients, it 
follows that 14.9% do not. This distribution was the same for patients with dementia. In patients 
with dementia, refraining from discussing biomarker sampling may reflect the perception that 
conveying this type of information is difficult due to impaired capacity to consent. However, even if 
the patients would be unable to give informed consent, a legal representative could substitute. 
Providing inadequate information to the patient prior to biomarker sampling is problematic for 
several reasons. For example, the patient has the rig t to both know and not know what their 
prognosis is 16. Thus, inadequate biomarker counselling may comproise non-maleficence or the 


















Another issue is that biomarkers may be perceived as potentially more harmful in MCI due to the 
uncertainty related to individual patient prognosis. Although the probability of progression from 
MCI to dementia on a group level is highly increased d pending on the biomarker status28, it is 
difficult to determine at the individual patient level, with some patients progressing after variable 
time periods, some remaining stable, and some reverting back to normal cognition 6,29–31. Modelling 
of the risk of progression at the individual patien level is underway 32 and likely to improve the 
ability of physicians to counsel patients about the individual risks of progression. The present study 
found that slightly more than half of respondents always or usually discussed the uncertainty of the 
biomarker results with their patients. In another study, in patients suspected of having dementia, 
physicians did not discuss the uncertainty related to the diagnosis in about a third of consultations 
33.  
 
Physicians in routine clinical settings may fail to undertake a discussion of the uncertainty 
regarding biomarkers for several different reasons. For example, they may be a lack of knowledge 
and unfamiliarity with (CSF) biomarker sampling, or generally a disbelieve that biomarkers are 
accurate, or variability in the distribution of the types of patients individual physicians are faced 
with. It may also be that the probability of conflicting biomarker results is high implying that the 
interpretation of AD biomarkers is complicated by multiple biomarker constellations 34. Or there 
may be a reluctance to introduce uncertainty into the diagnosis, or a belief that uncertainty may 
weaken the patients’ trust in the physician. In our st dy, around 60% always or usually included 
information on how biomarkers may help estimate the risk of progression. Physicians may also 
avoid prognostication due to various perceptions or feelings, such as a sense of discomfort in terms 

















derives from the moral value of respect for autonomy, is a central argument in favor of biomarker 
testing35. Furthermore, withholding information and dishonesty may have consequences for the 
patient-doctor relationship and thus, ultimately, for the patient 36. Moreover, not being open about 
the risk of progression may deprive the patient of the chance to plan for this eventuality. Lastly, 
evidence suggests that disclosing amyloid biomarker status is safe 37, which means that, with the 
right support and information, it is unharmful to be forthcoming about biomarker results. As 
always, an individualized approach is advisable as there also is a wish not to know their prognosis 
16,18,38. Indeed, comments from respondent in the present study indicate that they try to tailor 
information and diagnostic disclosure to avoid, e.g., not overwhelming the patient, which is a risk 
39.  
 
One way to ensure adequate pre and post biomarker counselling is to have guidelines available. A 
total of 28.3% of respondents reported that national r local guidelines were available on diagnostic 
disclosure of MCI, while 46.8% reported the same for dementia. This is in line with previous 
findings 23,40. To our knowledge, no international guidelines have been published on this topic, 
although some recommendations exist 41,42. Such guidelines would be relevant for centers with 
relatively easy access to biomarkers, but less so in areas where access is limited. 
  
Our study has limitations. Since we exclusively surveyed EADC expert centers, our findings may 
only be generalizable to tertiary centers with a high degree of specialization and access to 
biomarkers. In less specialized centers, using biomarkers may play a lesser role in diagnostic 
disclosure and MCI as a diagnosis may instead primarily be used to describe the functional level of 
patients rather than their clinico-biological trajectory. Nevertheless, our survey sample may reflect 

















Moreover, although we explicitly asked respondents to answer according to their actual practice, it 
is not possible to distinguish attitudes from actions. 
 
In conclusion, we found that biomarkers are widely used in patients with MCI, but that not all 
patients receive adequate pre- and post-biomarker counselling. Clinical dementia practice varied 
greatly across centers, which may indicate that physicians lack guidance on issues related to 
diagnostic disclosure, including biomarker counselling. Training that enhances communication 
skills may represent one way of improving diagnostic disclosure. At present, because disease-
modifying therapies are not available for patients with prodromal AD, additional emphasis must be 
put on preventive strategies, such as encouraging exercise and smoking cessation, but also on 
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Table 1. Individual physician characteristics 
 
Age, n† (%)  
n ≤40 years  50 (45.5) 
n >40 years 60 (54.5) 
Sex (female), n (%) (n=109) 64 (58.7) 
Specialists, n (%)  
Neurologist 60 (54.6) 
Geriatrician 10 (9.1) 
Psychiatrist 11 (10.0) 
Old age psychiatrist 8 (7.3) 
Other specialty 4 (3.6) 
No 17 (15.5) 
Clinical experience with dementia patients, n (%)  
≤5 years 32 (29.1) 

















Communications training  
Has received formal communications training 33 (32.4) 
Has not received formal communications training 77 (67.6) 




































Tend to discuss more in-depth 
with MCI† versus dementia‡  



















Discuss ability to diagnose 
underlying cause of MCI  
 




1.4% (n=1) 4.3% 
(n=3) 
0 0.002* 








































0.9% (n=1) 6.4% 
(n=7) 
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36.9% 
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9.6% 
(n=10)        
1.9% 
(n=2)        













(n=4)        
p<0.00001** 
Dementia 59.1% 








(n=3)        
Shows brain imaging when 
disclosing MCI diagnosis € 
 





















Use other aids when disclosing 
MCI diagnosis § 
 

































7.6% (n=8) 1.9% 
(n=2) 
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Actively recruiting refers to whether individual physicians at the time of the survey were actively recruiting patients 
with MCI to research trials 
† MCI: Mild cognitive impairment 
‡ Likert scale items for this question were: Very well, Well, Fairly well, Poorly, and Very poorly 
* P-values show results from Man-Whitney U test for independent samples comparing respondents actively recruiting 
patients with MCI. Non-significant results were found for age and years of experience for all question 




























Table 3. Disclosure of diagnosis and prognosis in MCI and dementia  
 
  Yes, regardless 
of whether the 
patient asks 
about it 
Only if the 
patient asks 
about it 
Never, even if the 
patient asks about 
it 
It depends on 
whether I think the 




    
MCI 54.3% 35.2% 0 10.5% 
Dementia 55.9% 34.3% 0 9.8% 
Possible/probable 
rate of progression 
    
MCI 30.5% 50.5% 8.6% 10.5% 
Dementia 30.4% 52.9% 2.9% 11.8% 
Possible future 
symptoms 

















MCI 22.9% 57.1% 5.7% 14.3% 
Dementia 33.3% 50.0% 1.0% 15.7% 
Possible underlying 
pathology  
    
MCI 51.9% 30.2% 2.8% 15.1% 
Dementia 71.8% 22.3% 0 5.8% 































The figure displays individual physicians’ evaluation of the value of biomarkers for predicting 


























































Figure 2. Terms used when disclosing a diagnosis of mild cognitive impairment 
 
 
The figure displays individual physicians’ response with regards to questions on language used 
when disclosing a diagnosis of MCI 
AD: Alzheimer’s disease  


























































































































Supplementary figure 2: Do you find that the following biomarkers are valuable in predicting the 































































Supplementary figure 3: When disclosing a diagnosis of dementia how often do you discuss the 
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